JP2023543131A5 - - Google Patents

Info

Publication number
JP2023543131A5
JP2023543131A5 JP2023513670A JP2023513670A JP2023543131A5 JP 2023543131 A5 JP2023543131 A5 JP 2023543131A5 JP 2023513670 A JP2023513670 A JP 2023513670A JP 2023513670 A JP2023513670 A JP 2023513670A JP 2023543131 A5 JP2023543131 A5 JP 2023543131A5
Authority
JP
Japan
Prior art keywords
hydroxypropyl
cyclodextrin
administration
therapeutically effective
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543131A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/048084 external-priority patent/WO2022047249A1/en
Publication of JP2023543131A publication Critical patent/JP2023543131A/ja
Publication of JP2023543131A5 publication Critical patent/JP2023543131A5/ja
Pending legal-status Critical Current

Links

JP2023513670A 2020-08-27 2021-08-27 シクロデキストリンによる心血管疾患の治療方法 Pending JP2023543131A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071257P 2020-08-27 2020-08-27
US63/071,257 2020-08-27
PCT/US2021/048084 WO2022047249A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cardiovascular disease with cyclodextrins

Publications (2)

Publication Number Publication Date
JP2023543131A JP2023543131A (ja) 2023-10-13
JP2023543131A5 true JP2023543131A5 (enExample) 2024-08-13

Family

ID=80353287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513670A Pending JP2023543131A (ja) 2020-08-27 2021-08-27 シクロデキストリンによる心血管疾患の治療方法

Country Status (14)

Country Link
US (2) US20240000826A1 (enExample)
EP (1) EP4203974A4 (enExample)
JP (1) JP2023543131A (enExample)
KR (1) KR20230104119A (enExample)
CN (1) CN116322644A (enExample)
AU (1) AU2021331487A1 (enExample)
CA (1) CA3189915A1 (enExample)
CO (1) CO2023003656A2 (enExample)
CR (1) CR20230135A (enExample)
IL (1) IL300805A (enExample)
JO (1) JOP20230043A1 (enExample)
MX (1) MX2023002418A (enExample)
PE (1) PE20231169A1 (enExample)
WO (1) WO2022047249A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.

Similar Documents

Publication Publication Date Title
JP2021502392A5 (enExample)
JP2022535127A5 (enExample)
JP2023501457A5 (enExample)
JP2014185161A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
US20250213504A1 (en) Methods of intravenously administering sotalol hydrochloride for the treatment of pediatric patients
JP5680412B2 (ja) レオヌリンの使用およびその組成物
AU2004275567B2 (en) Therapeutic treatment
JP2023543133A5 (enExample)
JP2024520020A5 (enExample)
JP2023543131A5 (enExample)
JP2023541170A5 (enExample)
Hajigholami et al. Comparing the efficacy of Dexeroyx (Osveral) and Deferoxamine (Desferal) in reducing serum ferritin level in patients with thalassemia major
EP1190714A2 (en) Method for the treatment of thromboembolic disorders in patients with aspirin resistance
JP2011502112A (ja) 抗ガン治療の副作用を治療するための新規組成物
CN113975276B (zh) 考比替尼在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
JP2025510311A5 (enExample)
Porter et al. Iron chelation
JP6420923B1 (ja) 医薬
WO2019004465A1 (ja) ペマフィブラートを含有する医薬
CN104000814B (zh) 一种防治痛风性关节炎的药物组合物及其用途
WO2022238884A1 (en) Dosing regimens
JP2025508660A5 (enExample)
US20240358726A1 (en) Specific therapeutic medical marijuana doses for stress and pain
AU2008201290B2 (en) Therapeutic treatment
JP2020045332A (ja) 慢性便秘症を治療するための医薬組成物